{"doi":"10.3390/ijerph191610159","title":"Real-World Evidence—Current Developments and Perspectives","abstract":"<jats:p>Real-world evidence (RWE) is increasingly involved in the early benefit assessment of medicinal drugs. It is expected that RWE will help to speed up approval processes comparable to RWE developments in vaccine research during the COVID-19 pandemic. Definitions of RWE are diverse, marking the highly fluid status in this field. So far, RWE comprises information produced from data routinely collected on patient’s health status and/or delivery of health care from various sources other than traditional clinical trials. These sources can include electronic health records, claims, patient-generated data including in home-use settings, data from mobile devices, as well as patient, product, and disease registries. The aim of the present update was to review current RWE developments and guidelines, mainly in the U.S. and Europe over the last decade. RWE has already been included in various approval procedures of regulatory authorities, reflecting its actual acceptance and growing importance in evaluating and accelerating new therapies. However, since RWE research is still in a transition process, and since a number of gaps in this field have been explored, more guidance and a consented definition are necessary to increase the implementation of real-world data.</jats:p>","journal":"International Journal of Environmental Research and Public Health","year":2022,"id":642097,"datarank":0.6476232170304466,"base_score":4.31748811353631,"endowment":4.31748811353631,"self_citation_contribution":0.6476232170304466,"citation_network_contribution":0.0,"self_endowment_contribution":0.6476232170304466,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":74,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":10,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1669881,"name":"Anja Thronicke","orcid":"0000-0002-6421-8290","position":1,"is_corresponding":false},{"id":1669880,"name":"Friedemann Schad","orcid":"0000-0002-6928-6209","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Real-World Evidence—Current Developments and Perspectives","abstract":"<jats:p>Real-world evidence (RWE) is increasingly involved in the early benefit assessment of medicinal drugs. It is expected that RWE will help to speed up approval processes comparable to RWE developments in vaccine research during the COVID-19 pandemic. Definitions of RWE are diverse, marking the highly fluid status in this field. So far, RWE comprises information produced from data routinely collected on patient’s health status and/or delivery of health care from various sources other than traditional clinical trials. These sources can include electronic health records, claims, patient-generated data including in home-use settings, data from mobile devices, as well as patient, product, and disease registries. The aim of the present update was to review current RWE developments and guidelines, mainly in the U.S. and Europe over the last decade. RWE has already been included in various approval procedures of regulatory authorities, reflecting its actual acceptance and growing importance in evaluating and accelerating new therapies. However, since RWE research is still in a transition process, and since a number of gaps in this field have been explored, more guidance and a consented definition are necessary to increase the implementation of real-world data.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":10,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36011793","pmcid":null,"openalex_id":null,"authors":[],"funders":[{"funder_name":"National Institutes of Health","grant_id":"1U01FD007172-01","title":"Transforming Real-world evidence with Unstructured and Structured data to advance Tailored therapy (TRUST)"},{"funder_name":"National Institutes of Health","grant_id":"1U01FD007206-01","title":"Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source"}],"total_grants":2,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1660-4601/19/16/10159/pdf?version=1660710169","host_type":"publisher"},{"url":"https://www.mdpi.com/1660-4601/19/16/10159/pdf","host_type":"publisher"},{"url":"https://doaj.org/article/b8be7b8913c34f54bc0b3b26b097d7b3","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/ijerph191610159","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9408280","host_type":"repository"},{"url":"https://doi.org/10.20944/preprints202207.0141.v1","host_type":""},{"url":"https://doi.org/10.3390/ijerph191610159","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/36011793","host_type":""},{"url":"http://dx.doi.org/10.3390/ijerph191610159","host_type":""}],"fields_of_study":["03 medical and health sciences","0302 clinical medicine"],"mesh_terms":[],"keywords":["Biomedical Research","Oncology and Oncogenics","COVID-19","Electronic Health Records","Humans","Medicine and Pharmacology","Review","Delivery of Health Care","Pandemics"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.24500858.v1","title":"Additional file 1 of Utilization of anonymization techniques to create an external control arm for clinical trial data","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.24500858","title":"Additional file 1 of Utilization of anonymization techniques to create an external control arm for clinical trial data","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602198.v1","title":"Additional file 1 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602198","title":"Additional file 1 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602204.v1","title":"Additional file 3 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602204","title":"Additional file 3 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602207.v1","title":"Additional file 4 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602207","title":"Additional file 4 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26602201","title":"Additional file 2 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26602201.v1","title":"Additional file 2 of A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot","publisher":"figshare","resource_type":"Dataset"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T21:33:05.095358Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}